Vishal Navani

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors

Sarah Cook, Vanessa Samuel, Daniel E. Meyers et al. · JAMA Network Open · 2024 · 152 citations · Full text

Life Sciences, Immunology, Oncology +16

Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma

Matthew Scott Ernst, Vishal Navani, J. Connor Wells et al. · European Urology · 2023 · 68 citations · Full text

Medicine, Biostatistics, Oncology +16

Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy

Alexander Watson, Siddhartha Goutam, Igor Stukalin et al. · JAMA Network Open · 2022 · 65 citations · Full text

Life Sciences, Immunology, Oncology +15

Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors

Daniel E. Meyers, Meghann Pasternak, Samantha Dolter et al. · JTO Clinical and Research Reports · 2023 · 31 citations · Full text

Medicine, Immunology, Oncology +17

Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Kosuke Takemura, Matthew Scott Ernst, Vishal Navani et al. · European Urology Oncology · 2023 · 27 citations

Medicine, Immunology, Oncology +14